在本次交易前 12 个月内，公司未发生与本次交易相关的购买、 出售资产的交易行为，不存在需要纳入累计计算范围的情形。 特此说明。 中成进出口股份有限公司董事会 《重组管理 办法》" ）的规定：上市公司在十二个月内连续对同一或者相关资产进 行购买、出售的，以其累计数分别计算相应数额。已按照《重组管理 办法》的规定编制并披露重大资产重组报告书的资产交易行为，无须 纳入累计计算的范围。中国证监会对《重组管理办法》第十三条第一 款规定的重大资产重组的累计期限和范围另有规定的，从其规定。交 易标的资产属于同一交易方所有或者控制，或者属于相同或者相近的 业务范围，或者中国证监会认定的其他情形下，可以认定为同一或者 相关资产。 ）。 中成进出口股份有限公司董事会 关于本次交易前 12 个月内购买、出售资产情况的说明 中成进出口股份有限公司（以下简称"公司"）拟发行股份购买 中国技术进出口集团有限公司持有的中技江苏清洁能源有限公司 根据《上市公司重大资产重组管理办法》 （以下简称" ...

关于本次交易采取的保密措施及保密制度的说明 中成进出口股份有限公司（以下简称"公司"、"上市公司"）拟 发行股份购买中国技术进出口集团有限公司持有的中技江苏清洁能 源有限公司 100%股权并同步募集配套资金（以下简称"本次交易" 现公司董事会就本次交易中的保密措施及保密制度说明如下： 中成进出口股份有限公司董事会 三、公司严格按照深圳证券交易所要求制作内幕信息知情人登记 表和交易进程备忘录，并及时报送深圳证券交易所。 四、公司多次督导、提示内幕信息知情人严格遵守保密制度，履 行保密义务，在内幕信息依法披露前，不得公开或泄露内幕信息，不 得利用内幕信息买卖公司股票。 五、公司聘请的独立财务顾问、法律顾问、审计机构、评估机构 等中介机构出具了保密承诺函，公司与上述中介机构签署的业务协议 中约定了保密相关内容，明确约定了保密信息的范围及保密责任。 六、筹划本次交易期间，为维护投资者利益，避免造成上市公司 股价异常波动，经上市公司向深圳证券交易所申请，上市公司股票自 七、本次交易涉及的《中成进出口股份有限公司发行股份购买资 产并募集配套资金暨关联交易报告书（草案）》依法披露后，公司将 向中国证券登记结算有限责任公司深 ...

中国银河证券股份有限公司作为本次交易的独立财务顾问，就上市公司本次交易前 根据《上市公司重大资产重组管理办法》第十四条规定："公司十二个月内连续对 同一或者相关资产进行购买、出售的，以其累计数分别计算相应数额。已按照本办法的 规定编制并披露重大资产重组报告书的资产交易行为，无须纳入累计计算的范围。中国 证监会对本办法第十三条第一款规定的重大资产重组的累计期限和范围另有规定的，从 其规定。交易标的资产属于同一交易方所有或者控制，或者属于相同或者相近的业务范 围，或者中国证监会认定的其他情形下，可以认定为同一或者相关资产。" 中国银河证券股份有限公司 关于中成进出口股份有限公司本次交易前十二个月内购买、出售 资产情况的核查意见 中成进出口股份有限公司（以下简称"公司"、"上市公司"）拟发行股份购买中国 技术进出口集团有限公司（以下简称"中技进出口"）持有的中技江苏清洁能源有限公 司（以下简称"标的公司"）100%股权并募集配套资金（以下简称"本次交易"、 "本次 重组"）。 财务顾问主办人： | 王文峰 | 冯学智 | 燕天 | | --- | --- | --- | | 杨哲 | 王飞 | | | | | 中国 ...

Group 1 - The company Zhongcheng Import and Export Co., Ltd. plans to acquire 100% equity of Jiangsu Clean Energy Co., Ltd. from China Technology Import and Export Group Co., Ltd. through a share issuance [1] - The company will also issue shares to no more than 35 specific investors to raise supporting funds for this transaction [1] - China Galaxy Securities Co., Ltd. acts as the independent financial advisor for this transaction, ensuring compliance with relevant laws and regulations [2][3] Group 2 - The independent financial advisor has conducted thorough due diligence and internal review, confirming the authenticity and completeness of the information provided by the parties involved in the transaction [2] - The advisor guarantees that their professional opinions are independent and that there are no substantial discrepancies with the disclosed documents from the company and the transaction counterparties [2] - Strict confidentiality measures and risk control protocols are in place to prevent insider trading and market manipulation [3]

（以下无正文） （本页无正文，为《中国银河证券股份有限公司关于本次交易相关主体不存在< 上市公司监管指引第 7 号——上市公司重大资产重组相关股票异常交易监管>第 十二条和 <深圳证券交易所上市公司自律监管指引第 ensp="ensp" 号="号" 重大资产重组="重大资产重 组"> 第 中国银河证券股份有限公司关于本次交易相关主体 不存在《上市公司监管指引第 7 号——上市公司重大资产 重组相关股票异常交易监管》第十二条和《深圳证券交易 所上市公司自律监管指引第 8 号——重大资产重组》第三 十条规定情形的核查意见 中国银河证券股份有限公司（以下简称"独立财务顾问"或"中国银河证券"） 受中成进出口股份有限公司（以下简称"中成股份"或"上市公司"）委托，担 任本次上市公司发行股份购买资产并募集配套资金暨关联交易（以下简称"本次 交易"）的独立财务顾问。 本独立财务顾问就本次交易相关主体不存在《上市公司监管指引第 7 号—— 上市公司重大资产重组相关股票异常交易监管》第十二条和《深圳证券交易所上 市公司自律监管指引第 8 号——重大资产重组》第三十条规定情形进行核查并发 表如下意见： 截至本核查意见出具日，本 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-080 上海奥浦迈生物科技股份有限公司 关于本次交易方案调整不构成重大调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海奥浦迈生物科技股份有限公司（以下简称"公司"或"上市公司"）拟 通过发行股份及支付现金方式购买澎立生物医药技术（上海）股份有限公司（以 下简称"澎立生物"或"标的公司"）100.00%股权（以下简称"本次发行股份及 支付现金购买资产"），并向不超过 35 名特定投资者发行股票募集配套资金（以 下简称"本次募集配套资金"，与本次发行股份及支付现金购买资产合称"本次 交易"）。 次会议，审议通过《关于调整公司发行股份及支付现金购买资产并募集配套资金 具体方案的议案》《关于确认公司本次交易方案调整不构成重大调整的议案》等 相关议案，对本次交易方案进行了调整。具体情况如下： 一、本次交易方案调整的具体内容 （一）本次募集配套资金金额 项 调整前 调整后 目 公司本次配套募集资金总额不超过 公司本次配套募集资金总额不超过 （二）本次募集配套 ...

Core Viewpoint - The adjustment of the transaction plan by Shanghai Aopumai Biotechnology Co., Ltd. does not constitute a significant change to the restructuring plan, as confirmed by the independent financial advisor [2][5]. Summary by Sections Transaction Plan Adjustment Details - The total amount of funds raised through the transaction has been reduced from 730 million yuan to 362.05 million yuan [3]. - The allocation of the raised funds has been modified, with the payment for cash consideration and taxes now accounting for a larger percentage of the total funds raised [3]. Fundraising Amount and Usage - The adjusted fundraising amount is 362.05 million yuan, with 1.48 million yuan allocated for intermediary fees, representing 4.08% of the total [3]. - The previous plan allocated 2 million yuan for intermediary fees, which was 2.74% of the total [3]. Confirmation of No Significant Adjustment - The adjustment does not involve changes to the transaction parties or the scope of the target assets, nor does it introduce new fundraising amounts, thus it is not considered a significant adjustment under relevant regulations [4][5]. - The criteria for determining significant adjustments to restructuring plans were referenced, confirming that the current adjustments fall within acceptable limits [4]. Decision-Making Process for the Adjustment - The adjustment was approved in the 13th meeting of the second board of directors and the 12th meeting of the second supervisory board, following prior review by the strategic committee and independent directors [5]. Independent Financial Advisor's Opinion - The independent financial advisor has verified that the transaction plan adjustment does not constitute a significant change according to the relevant regulations [5].

Core Viewpoint - The report provides an independent financial advisory opinion regarding Shanghai Aopumai Biotechnology Co., Ltd.'s issuance of shares and cash payment for asset acquisition, emphasizing the fairness and reasonableness of the transaction for all shareholders [1][2][3]. Group 1: Transaction Overview - The transaction involves the acquisition of 100% equity of Pengli Biotechnology by issuing shares and cash, along with raising supporting funds [10][20]. - The total transaction price for the acquisition is approximately 1.45 billion yuan, with the payment structured through both shares and cash [18][19]. Group 2: Compliance with Regulations - The transaction complies with the relevant provisions of the Major Asset Restructuring Management Measures and does not constitute a restructuring listing as defined by the regulations [14][15]. - The transaction has been assessed to meet the requirements of the Science and Technology Innovation Board's continuous supervision measures and listing rules [21]. Group 3: Financial and Operational Impact - The acquisition is expected to enhance the company's asset quality and operational capabilities, allowing for a more comprehensive service offering in the biopharmaceutical sector [15][16]. - The target company, Pengli Biotechnology, specializes in preclinical drug research services, which aligns with the acquirer's existing business in cell culture and contract development manufacturing (CDMO) [8][20]. Group 4: Independent Advisory and Due Diligence - The independent financial advisor has conducted thorough due diligence and confirmed that the transaction's terms are fair and reasonable, ensuring no substantial discrepancies with disclosed documents [2][11]. - The advisor's opinion is based on the assumption that all parties involved will adhere to their contractual obligations and that the provided information is accurate and complete [3][4].

Core Viewpoint - The board of Zhejiang Zhenyang Development Co., Ltd. confirms that there are no circumstances under which the parties involved in the merger with Zhejiang Huhangning Expressway Co., Ltd. are prohibited from participating in the major asset restructuring as per the relevant regulations [1][2]. Summary by Relevant Sections - The transaction involves Zhejiang Huhangning issuing A-shares to all shareholders of Zhenyang Development for a share swap merger [1]. - The board states that all parties involved, including controlling shareholders and management, have not been subject to any investigations or penalties related to insider trading in the last 36 months [1][2]. - The board's statement serves to clarify compliance with the regulatory guidelines regarding major asset restructuring and abnormal trading [2].

Group 1 - The core point of the article is that Zhejiang Zhenyang Development Co., Ltd. and Zhejiang Huhangyong Expressway Co., Ltd. are planning a share swap merger, where Zhejiang Huhangyong will issue A-shares to acquire all shareholders of Zhenyang Development [1] - The board of Zhenyang Development conducted a thorough analysis and concluded that the transaction complies with Article 11 of the Major Asset Restructuring Management Measures for Listed Companies [1] - The board confirmed that the transaction adheres to legal and regulatory requirements, ensuring that the company meets the conditions for stock listing and that debt handling is lawful [1]